Stock listing
OTC:PTIX Protagenic Therapeutics, Inc. Stock
Follow Protagenic Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · OTC:PTIX
$0.38 USD -0.07 (-15.6%)
Close on Nov 20, 2026
- Day range
- $0.353 – $0.48 USDNov 20, 2026
- Volume
- 15,513 sharesNov 20, 2026
- Market cap
- $687,879 USDAt the close on Nov 20, 2026 · price × 1.81M shares outstanding
- 52-week range
- $0.128 – $2.38 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $10,037 USDMedian day 1,300 shares · 7 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:PTIX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.38 | -0.07 | -15.6% | $0.405 | $0.48 | $0.353 | 15,513 | |
| $0.45 | -0.008 | -1.6% | $0.45 | $0.45 | $0.45 | 500 | |
| $0.458 | +0.008 | +1.7% | $0.458 | $0.458 | $0.458 | 1,062 | |
| $0.45 | -0.022 | -4.6% | $0.45 | $0.45 | $0.45 | 601 | |
| $0.472 | 0.00 | 0.0% | $0.472 | $0.472 | $0.472 | 502 | |
| $0.472 | -0.038 | -7.5% | $0.472 | $0.472 | $0.472 | 104 | |
| $0.51 | 0.00 | 0.0% | $0.51 | $0.51 | $0.51 | 790 | |
| $0.51 | -0.025 | -4.8% | $0.53 | $0.53 | $0.51 | 3,000 | |
| $0.536 | -0.005 | -0.8% | $0.54 | $0.54 | $0.536 | 1,104 | |
| $0.54 | -0.09 | -14.3% | $0.63 | $0.63 | $0.536 | 7,501 | |
| $0.63 | 0.00 | 0.0% | $0.63 | $0.63 | $0.63 | 134 | |
| $0.63 | -0.02 | -3.1% | $0.63 | $0.63 | $0.63 | 139 | |
| $0.65 | +0.03 | +4.8% | $0.66 | $0.66 | $0.65 | 1,000 | |
| $0.62 | -0.018 | -2.8% | $0.62 | $0.62 | $0.62 | 1,006 | |
| $0.638 | -0.008 | -1.2% | $0.638 | $0.638 | $0.638 | 2,700 | |
| $0.646 | -0.007 | -1.1% | $0.648 | $0.648 | $0.642 | 1,700 | |
| $0.653 | 0.00 | 0.0% | $0.653 | $0.653 | $0.653 | 0 | |
| $0.653 | +0.005 | +0.8% | $0.653 | $0.653 | $0.653 | 100 | |
| $0.648 | -0.072 | -10.0% | $0.72 | $0.72 | $0.648 | 3,500 | |
| $0.72 | -0.015 | -2.0% | $0.72 | $0.72 | $0.72 | 900 | |
| $0.735 | +0.015 | +2.1% | $0.735 | $0.735 | $0.735 | 500 | |
| $0.72 | -0.03 | -4.0% | $0.72 | $0.72 | $0.72 | 100 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | 0.00 | 0.0% | $0.763 | $0.763 | $0.75 | 1,300 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | -0.05 | -6.3% | $0.75 | $0.75 | $0.75 | 200 | |
| $0.80 | -0.006 | -0.7% | $0.80 | $0.80 | $0.80 | 800 | |
| $0.806 | 0.00 | 0.0% | $0.806 | $0.806 | $0.806 | 1,100 | |
| $0.806 | +0.036 | +4.7% | $0.75 | $0.806 | $0.75 | 1,000 | |
| $0.77 | 0.00 | 0.0% | $0.77 | $0.77 | $0.77 | 0 | |
| $0.77 | 0.00 | 0.0% | $0.77 | $0.77 | $0.77 | 0 | |
| $0.77 | 0.00 | 0.0% | $0.77 | $0.77 | $0.77 | 0 | |
| $0.77 | -0.004 | -0.5% | $0.786 | $0.786 | $0.77 | 2,000 | |
| $0.774 | 0.00 | 0.0% | $0.774 | $0.774 | $0.774 | 0 | |
| $0.774 | -0.006 | -0.8% | $0.78 | $0.78 | $0.774 | 1,200 | |
| $0.78 | -0.03 | -3.7% | $0.80 | $0.801 | $0.78 | 5,700 | |
| $0.81 | +0.002 | +0.2% | $0.832 | $0.832 | $0.81 | 900 | |
| $0.808 | +0.028 | +3.6% | $0.82 | $0.82 | $0.808 | 1,200 | |
| $0.78 | +0.006 | +0.8% | $0.774 | $0.78 | $0.774 | 300 | |
| $0.774 | -0.042 | -5.1% | $0.805 | $0.805 | $0.774 | 4,100 | |
| $0.816 | -0.044 | -5.1% | $0.816 | $0.816 | $0.816 | 1,300 | |
| $0.86 | 0.00 | 0.0% | $0.87 | $0.87 | $0.86 | 2,400 | |
| $0.86 | -0.046 | -5.1% | $0.865 | $0.884 | $0.86 | 800 | |
| $0.906 | -0.008 | -0.9% | $0.914 | $0.93 | $0.906 | 3,400 | |
| $0.914 | +0.185 | +25.4% | $0.73 | $0.914 | $0.73 | 33,500 | |
| $0.729 | -0.111 | -13.2% | $0.769 | $0.769 | $0.729 | 10,300 | |
| $0.84 | +0.05 | +6.3% | $0.77 | $0.84 | $0.765 | 3,300 | |
| $0.79 | -0.04 | -4.8% | $0.81 | $0.81 | $0.79 | 11,400 | |
| $0.83 | -0.041 | -4.7% | $0.808 | $0.85 | $0.808 | 6,700 | |
| $0.871 | 0.00 | 0.0% | $0.81 | $0.871 | $0.81 | 400 | |
| $0.871 | -0.049 | -5.3% | $0.90 | $0.90 | $0.81 | 3,100 | |
| $0.92 | -0.106 | -10.3% | $0.91 | $0.938 | $0.85 | 28,100 | |
| $1.026 | -0.034 | -3.2% | $1.00 | $1.09 | $0.90 | 25,800 | |
| $1.06 | +0.06 | +6.0% | $0.95 | $1.06 | $0.95 | 1,700 | |
| $1.00 | -0.05 | -4.8% | $1.02 | $1.02 | $0.95 | 10,700 | |
| $1.05 | -0.14 | -11.8% | $1.19 | $1.19 | $1.05 | 17,700 | |
| $1.19 | -0.01 | -0.8% | $1.225 | $1.24 | $1.13 | 26,200 | |
| $1.20 | +0.22 | +22.4% | $1.11 | $1.23 | $1.11 | 30,100 | |
| $0.98 | +0.045 | +4.8% | $0.935 | $1.11 | $0.935 | 45,800 | |
| $0.935 | +0.045 | +5.1% | $0.85 | $0.935 | $0.77 | 36,600 | |
| $0.89 | -0.06 | -6.3% | $0.95 | $1.01 | $0.864 | 18,000 | |
| $0.95 | -0.14 | -12.8% | $1.18 | $1.20 | $0.85 | 43,400 | |
| $1.09 | +0.289 | +36.1% | $0.85 | $1.32 | $0.85 | 115,600 | |
| $0.801 | +0.201 | +33.5% | $0.649 | $0.91 | $0.63 | 140,600 | |
| $0.60 | +0.25 | +71.4% | $0.40 | $0.613 | $0.40 | 40,700 |
Splits
4 splits since 2007 · OTC:PTIX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-14 | Consolidation | |
| 1-for-4 | Consolidation | |
| 1-for-4 | Consolidation | |
| 1-for-300 | Consolidation |
- Ticker
- OTC:PTIX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news
Protagenic Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 1 in the last 12 months · 1 in all · newest Nov 11, 2026 · oldest 2026
- Calls
- 1 call with a replay · 1 with a transcript · latest Apr 1, 2024
- Decks
- 4 decks · latest August 2021
Valuation
Price/book 0.6× against a median of 0.2×: 7th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $610,970 USD
- P/E
- 0.1×
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.6×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.21
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Protagenic Therapeutics, Inc. · OTC:PTIX | US$687,879 | US$610,970 | 0.1× | n/a | n/a | 0.6× | n/a | 0.0× | 1.21 |
| Valion Bio, Inc. · NASDAQ:VBIO | US$1.04M | US$16.34M | n/a | 42.8× | n/a | 0.2× | n/a | 4.1× | 1.11 |
| GeoVax Labs, Inc. · NASDAQ:GOVX | US$985,460 | −US$915,033 | n/a | n/a | n/a | 0.9× | n/a | 0.2× | 1.47 |
| Biodexa Pharmaceuticals plc · NASDAQ:BDRX | US$982,950 | −US$3.22M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.01 |
| Gabather AB · OMXSTO:GABA | US$919,514 | US$559,105 | n/a | n/a | n/a | 6.4× | n/a | 0.0× | n/a |
| ExpreS2ion Biotech Holding AB · OMXSTO:EXPRS2 | US$792,634 | −US$2.43M | n/a | −6.5× | n/a | 0.2× | −935.9% | 0.0× | n/a |
| Silexion Therapeutics Corp · NASDAQ:SLXN | US$790,001 | −US$3.60M | n/a | n/a | n/a | 0.3× | n/a | 0.1× | 2.77 |
| Oragenics Inc. · AMEX:OGEN | US$708,377 | −US$1.12M | n/a | n/a | n/a | 0.7× | n/a | 0.4× | 1.47 |
| Lakewood-Amedex Biotherapeutics Inc. · NASDAQ:LABT | US$580,337 | −US$2.74M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 0.46 |
| Mushrooms, Inc. · OTC:MSRM | US$539,339 | US$564,177 | n/a | n/a | n/a | n/a | n/a | n/a | 1.24 |
| Jaguar Health, Inc. · NASDAQ:JAGX | US$527,406 | −US$1.48M | n/a | −0.1× | n/a | 0.0× | −181.8% | 0.2× | 3.75 |
| Median of the others | US$791,318 | −US$1.30M | −0.1× | 0.2× | −558.9% | 0.1× | 1.36 |
Team and board
| Officer | Role |
|---|---|
| Andrew Slee | Chief Development Officer |
Events
Calls
| Call | When | Status |
|---|---|---|
| Protagenic Therapeutics (OTC:PTIX) Q4 2023 Earnings Call | Mon, Apr 01, 2024 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q2 2027 | Nov 17, 2026 | 0.0% |
| Q1 2027 | Aug 31, 2026 | +21.4% |
| Q4 2026 | Jun 3, 2026 | 0.0% |
| Q3 2026 | Feb 25, 2026 | +9.4% |
| Q2 2026 | Nov 26, 2025 | −4.5% |
| Q1 2026 | Aug 29, 2025 | +1.1% |
| Q4 2025 | May 13, 2025 · After close | −6.5% |
| Q3 2025 | Mar 31, 2025 · Before open | −13.3% |
| Q2 2025 | Nov 12, 2024 · After close | −18.8% |
| Q1 2025 | Aug 14, 2024 · After close | −15.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2024 | May 15, 2024 · After close | +7.2% |
| Q2 2024 | Nov 14, 2023 · After close | 0.0% |
| Q1 2024 | Aug 14, 2023 · After close | 0.0% |
| Q4 2023 | May 15, 2023 · After close | −9.6% |
| Q4 2022 | Mar 31, 2023 · After close | +4.6% |
| Q2 2023 | Nov 14, 2022 · After close | −0.4% |
| Q1 2023 | Aug 11, 2022 · After close | −1.9% |
| Q4 2022 | Apr 7, 2022 · After close | +0.2% |
| Q4 2021 | Mar 2, 2022 | −3.2% |
| Q2 2022 | Nov 15, 2021 · After close | −2.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2021) | Investor deck | 28 slides | August 2021 |
| Protagenic Therapeutics, Inc.\new — Investor Presentation (April 2021) | Investor deck | 28 slides | Apr 21, 2021 |
| Protagenic Therapeutics, Inc.\new — Investor Presentation (April 2021) | Investor deck | 28 slides | Apr 8, 2021 |
| Traffix — Merger or Acquisition (December 2007) | Merger or acquisition | 30 slides | Dec 5, 2007 |
Financings
| Raise | Date |
|---|---|
| Private placement of shares of common stock, pre-funded warrants and common warrants Announced: US$1.5M–US$5M · two series of milestone-linked warrants that may provide up to $3.5 million in… · Brookline Capital Markets, a division of Arcadia Securities, LLC Dealers: Brookline Capital Markets, a division of Arcadia Securities, LLC (lead) Use of proceeds: Complete IND-enabling activities for PT00114, start its Phase 1/2a trial in Generalized Anxiety Disorder, and working capital and general corporate purposes | Nov 11, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2025 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of revenue | 37.7K | 50.3K | 28.2K | 30 | 286 | 339 | 347 | |||
| Gross profit | -37.7K | -50.3K | -28.2K | -30 | -286 | -339 | -347 | |||
| Research and development | 901.9K | 1.70M | 376.7K | 3.84M | 3.06M | 1.59M | 1.14M | 699.8K | 807.9K | 881.2K |
| Selling, general and administrative | 1.70M | 1.76M | 1.21M | 1.97M | 3.00M | 1.85M | 1.28M | 1.43M | ||
| Operating income | -4.50M | -5.83M | -2.59M | -5.70M | -4.53M | -3.56M | -4.14M | -2.55M | -2.09M | -2.31M |
| Depreciation and amortization | 49.2K | 37.7K | 50.3K | 28.2K | 30 | 427 | 286 | 339 | 347 | |
| EBITDA | -4.45M | -5.79M | -5.65M | -4.50M | -3.56M | -4.14M | -2.55M | -2.09M | -2.31M | |
| Interest expense | 296.9K | 0 | 107.7K | 137.5K | 496.9K | 246.2K | 15.9K | 2.79K | ||
| Income before tax | 1.37M | -5.16M | -3.59M | -5.53M | -5.00M | -3.56M | -4.52M | -2.55M | -1.75M | -2.56M |
| Income tax | 2 | 46.1K | 463.7K | 246.2K | 15.9K | 486.8K | ||||
| Net income | 1.37M | -5.16M | -3.59M | -5.53M | -5.00M | -3.56M | -4.52M | -2.55M | -1.75M | -2.56M |
| Earnings per share, basic | 0.59 | -2.66 | -0.67 | -1.13 | -1.15 | -0.82 | -1.24 | -0.25 | -0.17 | -0.25 |
| Earnings per share, diluted | 0.59 | -0.67 | -1.13 | -1.15 | -0.82 | -0.31 | -0.25 | -0.17 | -0.25 |
Balance sheet
| Line | FY2026 | FY2025 | FY2025 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.51M | 2.21M | 14.5K | 1.84M | 1.29M | 215.2K | 541.2K | 671.1K | 798.6K | 362.5K |
| Short-term investments | 0 | 2.77M | 7.76M | 9.83M | 0 | 250.4K | 250.4K | |||
| Receivables | 41.5K | |||||||||
| Inventory | 1.07K | 1.04K | 0 | |||||||
| Current assets | 1.54M | 2.30M | 89.1K | 1.88M | 4.20M | 8.04M | 11.1M | 879.2K | 842.0K | 696.3K |
| Property, plant and equipment | 14.6K | 60.5K | 73.0K | 123.3K | 1.77K | 296 | 611 | |||
| Goodwill | 0 | |||||||||
| Total assets | 3.65M | 2.13M | 89.1K | 1.96M | 4.32M | 8.04M | 11.1M | 879.2K | 842.3K | 696.9K |
| Accounts payable | 949.5K | 2.03M | 961.1K | 103.0K | 113.8K | 155.5K | 279.0K | 141.9K | 163.0K | 10.0K |
| Current liabilities | 1.03M | 6.82M | 5.04M | 942.8K | 655.3K | 1.12M | 799.5K | 655.2K | 1.20M | 907.8K |
| Long-term debt | 318.4K | 1.37M | 279.4K | 0 | ||||||
| Total debt | 3.16M | 344.2K | 318.4K | 1.37M | 279.4K | |||||
| Total liabilities | 1.03M | 6.82M | 5.04M | 942.8K | 655.3K | 1.12M | 1.12M | 2.03M | 1.48M | 907.8K |
| Shareholders' equity | 2.62M | -2.39M | -4.95M | -3.32M | 3.67M | 6.92M | 9.94M | -1.15M | -634.4K | -210.9K |
| Shares outstanding | 1.81M | 1.93M | 5.80M | 517.3K | 4.44M | 4.32M | 4.30M | 10.4M | 10.3M | 10.3M |
Cash flow
| Line | FY2026 | FY2025 | FY2025 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -2.81M | -4.14M | -1.77M | -4.22M | -3.70M | -1.99M | -2.80M | -1.35M | -488.0K | -1.07M |
| Capital spending | -3.30K | -3 | 0 | -149.8K | -1.80K | -4 | 0 | 0 | 0 | |
| Free cash flow | -2.81M | -4.14M | -4.22M | -3.85M | -2.00M | -2.80M | -1.35M | -488.0K | -1.07M | |
| Cash from investing | 629.9K | 943.2K | 2.80M | 4.78M | 1.60M | -9.91M | -9.91M | 250.0K | 1.05M | |
| Cash from financing | 3.87M | 4.51M | 1.81M | 1.96M | 0 | 0 | 12.6M | 1.22M | 670.0K | 670.0K |
| Dividends paid | 0 | |||||||||
| Share buybacks | 0 | |||||||||
| Change in cash | 1.70M | 4.46M | 40.4K | 550.6K | 1.07M | -326.0K | -129.9K | -127.5K | 436.1K | -37.2K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 17, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2026 | Material contract | SEC |
| 4 · Change in ownership | Aug 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 20, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 19, 2026 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Aug 14, 2026 | Explanation request | SEC |
| 10-K · Annual report | Aug 14, 2026 | Annual report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| NT 10-K · Late filing notice | Jun 30, 2026 | Explanation request | SEC |
| 8-K · Current report | Apr 6, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | Mar 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Mar 2, 2026 | Management or board change | SEC |
| 8-K · Current report | Feb 23, 2026 | Acquisition or disposal | SEC |
| NT 10-Q · Late filing notice | Feb 18, 2026 | Explanation request | SEC |
| 25-NSE | Jan 23, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 5, 2026 | Current report | SEC |
| DEF 14A · Proxy statement | Dec 5, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 26, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 26, 2025 | Current report | SEC |
| NT 10-Q · Late filing notice | Nov 14, 2025 | Explanation request | SEC |
| 8-K · Current report | Nov 5, 2025 | Management or board change | SEC |
| 8-K · Current report | Oct 31, 2025 | Current report | SEC |
| 424B5 · Prospectus | Oct 24, 2025 | Offer document | SEC |
| 3 · Initial statement of ownership | Oct 24, 2025 | Insider trade | SEC |
| 8-K/A · Current report, amended | Sep 17, 2025 | Current report | SEC |
| 10-QT | Sep 10, 2025 | Other filings | SEC |
| 8-K/A · Current report, amended | Aug 27, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 25, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 22, 2025 | Current report | SEC |
| NT 10-Q · Late filing notice | Aug 14, 2025 | Explanation request | SEC |
| 8-K · Current report | Aug 13, 2025 | Management or board change | SEC |
| 8-K · Current report | Jul 30, 2025 | Current report | SEC |
| 8-K · Current report | Jul 24, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 8, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 27, 2025 | Current report | SEC |
| 8-K · Current report | May 21, 2025 | Current report | SEC |
| 8-K · Current report | May 20, 2025 | Material contract | SEC |
| DEFA14A · Additional proxy material | May 19, 2025 | Meeting notice | SEC |
| 8-K · Current report | May 19, 2025 | Acquisition or disposal | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2025 | Current report | SEC |
| 8-K · Current report | Apr 29, 2025 | Current report | SEC |
| 8-K · Current report | Apr 18, 2025 | Meeting outcome | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Mar 7, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Feb 27, 2025 | Meeting notice | SEC |
| 8-K · Current report | Feb 24, 2025 | Management or board change | SEC |
| 8-K · Current report | Feb 21, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 29, 2025 | Current report | SEC |
| 8-K · Current report | Jan 15, 2025 | Current report | SEC |
| 8-K · Current report | Jan 10, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jan 10, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 10, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 7, 2025 | Other filings | SEC |
| S-3/A · Registration statement, amended | Jan 7, 2025 | Offer document | SEC |
| DEFA14A · Additional proxy material | Jan 6, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jan 3, 2025 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Dec 30, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Dec 27, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 27, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 23, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 20, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 20, 2024 | Other filings | SEC |
| S-1 · Registration statement | Dec 20, 2024 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Dec 19, 2024 | Meeting notice | SEC |
| 8-K · Current report | Dec 3, 2024 | Current report | SEC |
| 8-K · Current report | Nov 22, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2024 | Current report | SEC |
| 8-K · Current report | Oct 29, 2024 | Material contract | SEC |
| 8-K · Current report | Sep 17, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 26, 2024 | Current report | SEC |
| UPLOAD · Letter from the SEC | Jun 18, 2024 | Other filings | SEC |
| S-3 · Registration statement | Jun 14, 2024 | Offer document | SEC |
| 8-K · Current report | May 24, 2024 | Current report | SEC |
| 8-K · Current report | May 22, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | May 14, 2024 | Annual report | SEC |
| 10-K/A · Annual report, amended | Apr 23, 2024 | Annual report | SEC |
| 4 · Change in ownership | Apr 1, 2024 | Insider trade | SEC |
| 10-K · Annual report | Apr 1, 2024 | Annual report | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 21, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Dec 15, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Nov 29, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Nov 2, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Oct 13, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 10-Q · Quarterly report | May 15, 2023 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Apr 17, 2023 | Annual report | SEC |
| 10-K · Annual report | Mar 31, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 22, 2023 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Nov 28, 2022 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Nov 14, 2022 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Oct 11, 2022 | Meeting notice | SEC |
| 8-K · Current report | Sep 2, 2022 | Current report | SEC |
| 10-Q · Quarterly report | Aug 11, 2022 | Quarterly report | SEC |
| 8-K · Current report | Jun 29, 2022 | Current report | SEC |
| 4 · Change in ownership | May 18, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | May 13, 2022 | Quarterly report | SEC |
| 10-K · Annual report | Apr 7, 2022 | Annual report | SEC |
| NT 10-K · Late filing notice | Mar 31, 2022 | Explanation request | SEC |
| S-8 · Registration statement for employee plans | Mar 8, 2022 | Offer document | SEC |
| SC 13G · Big-stake notice | Feb 14, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 4, 2022 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 15, 2021 | Quarterly report | SEC |
| 8-K · Current report | Oct 5, 2021 | Current report | SEC |
| 8-K · Current report | Oct 1, 2021 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | Sep 20, 2021 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 14, 2021 | Other filings | SEC |
| S-3/A · Registration statement, amended | Sep 10, 2021 | Offer document | SEC |
| DEF 14A · Proxy statement | Sep 8, 2021 | Meeting notice | SEC |
| 8-K · Current report | Aug 18, 2021 | Current report | SEC |
| UPLOAD · Letter from the SEC | Aug 18, 2021 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 16, 2021 | Quarterly report | SEC |
| S-3 · Registration statement | Aug 13, 2021 | Offer document | SEC |
| 8-K · Current report | Jul 23, 2021 | Current report | SEC |
| 8-K · Current report | Jul 2, 2021 | Material contract | SEC |
| 424B5 · Prospectus | Jul 2, 2021 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 24, 2021 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 21, 2021 | Other filings | SEC |
| S-3/A · Registration statement, amended | Jun 21, 2021 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jun 11, 2021 | Other filings | SEC |
| S-3 · Registration statement | Jun 4, 2021 | Offer document | SEC |
| 4 · Change in ownership | Jun 3, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2021 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2021 | Insider trade | SEC |
| 10-Q · Quarterly report | May 17, 2021 | Quarterly report | SEC |
| 4 · Change in ownership | May 5, 2021 | Insider trade | SEC |
| 4 · Change in ownership | May 3, 2021 | Insider trade | SEC |
| 8-K · Current report | Apr 30, 2021 | Material contract | SEC |
| 424B4 · Prospectus | Apr 28, 2021 | Offer document | SEC |
| 424B4 · Prospectus | Apr 28, 2021 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 27, 2021 | Other filings | SEC |
| S-1MEF · Registration of more shares for the same offering | Apr 26, 2021 | Offer document | SEC |
| CERT · Exchange's certificate of listing | Apr 26, 2021 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Apr 26, 2021 | Other filings | SEC |
| S-1/A · Registration statement, amended | Apr 26, 2021 | Offer document | SEC |
| S-1/A · Registration statement, amended | Apr 23, 2021 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 23, 2021 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 23, 2021 | Other filings | SEC |
| S-1/A · Registration statement, amended | Apr 23, 2021 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 22, 2021 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 22, 2021 | Other filings | SEC |
| 8-K · Current report | Apr 21, 2021 | Current report | SEC |
| CORRESP · Letter to the SEC | Apr 21, 2021 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 21, 2021 | Other filings | SEC |
| S-1/A · Registration statement, amended | Apr 9, 2021 | Offer document | SEC |
| 8-K · Current report | Apr 7, 2021 | Current report | SEC |
| S-1/A · Registration statement, amended | Apr 7, 2021 | Offer document | SEC |
| 10-K · Annual report | Mar 25, 2021 | Annual report | SEC |
| S-8 · Registration statement for employee plans | Mar 10, 2021 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Feb 22, 2021 | Other filings | SEC |
| S-1 · Registration statement | Feb 11, 2021 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 10, 2021 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 16, 2020 | Quarterly report | SEC |
| 8-K · Current report | Oct 7, 2020 | Meeting outcome | SEC |
| 8-K · Current report | Sep 3, 2020 | Material contract | SEC |
| DEF 14A · Proxy statement | Aug 28, 2020 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2020 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 21, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2020 | Insider trade | SEC |
| 8-K · Current report | Jul 21, 2020 | Management or board change | SEC |
| 8-K · Current report | Jul 9, 2020 | Material contract | SEC |
| 10-Q · Quarterly report | Jun 18, 2020 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2020 | Material contract | SEC |
| 8-K · Current report | May 8, 2020 | Current report | SEC |
| 10-K · Annual report | Apr 28, 2020 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2020 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 11, 2020 | Offer document | SEC |
| 8-K · Current report | Mar 2, 2020 | Material contract | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 28, 2020 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 26, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2020 | Insider trade | SEC |
| 5 · Annual statement of ownership | Feb 24, 2020 | Insider trade | SEC |
| 5 · Annual statement of ownership | Feb 24, 2020 | Insider trade | SEC |
| 8-K · Current report | Jan 29, 2020 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Jan 27, 2020 | Other filings | SEC |
This page holds 200 of 708 filings. Open Filings
Cap table
Built by 6ix from Protagenic Therapeutics, Inc.’s releases · as of Nov 11, 2026
- Common shares
- 1,810,208
- Fully diluted
- 1,810,208
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 1,810,208 | Nov 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 1,810,208 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Joshua N. Silverman Other companies: Femasys Inc. (Director · Since at least Nov 21, 2023); PharmaCyte Biotech, Inc. (Interim Chief Executive Officer, President, and Director · Since at least Aug 15, 2022); TAO Synergies Inc. (Executive Chairman · Since at least Jun 4, 2021); Petros Pharmaceuticals Inc (Vice-Chairman of the Board · Since at least Dec 1, 2020); Q/C Technologies, Inc. (Executive Chairman · Since at least Sep 6, 2018); Fabric.AI, Inc. (Chief Executive Officer, Director · Since at least Aug 15, 2016); Marker Therapeutics, Inc. (Director · Nov 28, 2016 – Oct 16, 2018 · Past); Neurotrope Inc (Director · Aug 4, 2016 – Dec 1, 2020 · Past); MGT Capital Investments, Inc. (Director · Dec 31, 2015 – Dec 31, 2015 · Past); National Holdings Corporation (Director · Jul 28, 2014 – Sep 12, 2016 · Past) | Director · Feb 12, 2016 – Feb 21, 2020 · Past |
| Susan Swenson Other companies: Faraday Future Intelligent Electric Inc. (Executive Chairperson, Director · Jul 21, 2021 – Jan 31, 2022 · Past); DNA X, Inc. (Director · May 9, 2019 – Nov 12, 2021 · Past); Vislink Technologies, Inc. (Director · Oct 19, 2018 – Feb 16, 2022 · Past); Inseego Corp. (Chief Executive Officer, Director · Jun 8, 2012 – May 12, 2017 · Past); Harmonic Inc. (Director · Feb 29, 2012 – Feb 15, 2024 · Past); Wells Fargo & Company (Director · Mar 21, 2006 – Apr 25, 2017 · Past) | Chief Operating Officer · Aug 20, 2007 – Dec 31, 2007 · Past |
| Alexander K Arrow Other companies: EUDA Health Holdings Limited (Director · Nov 22, 2021 – Nov 22, 2021 · Past); 8I Enterprises Acquisition Corp (Director · Mar 27, 2019 – Mar 27, 2019 · Past) | Chief Financial Officer · Oct 16, 2017 – Mar 25, 2024 · Past |
| Brian Corvese Other companies: MiNK Therapeutics, Inc. (Director · Since at least Oct 13, 2021); Agenus Inc. (Director · Since at least Dec 17, 2020) | Director · Mar 25, 2024 – Mar 25, 2024 · Past |
| Jennifer Buell Other companies: MiNK Therapeutics, Inc. (President and CEO · Since at least Oct 13, 2021); Agenus Inc. (President and CEO of MiNK Therapeutics and Chairman, Executive Council at Agenus · Since at least Jun 29, 2017) | Director · Jul 18, 2020 – Mar 25, 2024 · Past |
| Barrett Evans Other companies: APPlife Digital Solutions, Inc. (CFO, Director · Since at least Jun 13, 2025) | ex CEO, Director · May 15, 2025 – May 15, 2025 · Past |
| Jay Wolf Other companies: Digital Turbine, Inc. (Chief Financial Officer, Director · Oct 12, 2006 – Mar 4, 2009 · Past) | Director · Oct 24, 2006 – Oct 24, 2006 · Past |
| Jeffrey A Schwartz Other companies: CarParts.com, Inc. (Director · Oct 22, 2007 – Jun 2, 2011 · Past) | Chief Executive Officer, Director · Nov 11, 2008 – Jan 27, 2010 · Past |
| Mark Dyne Other companies: Talon International, Inc. (Director · Apr 22, 2008 – Sep 11, 2015 · Past) | Director · Nov 11, 2008 – Sep 28, 2010 · Past |
| Nathan Yu-Gai Fong Other companies: Orchard Enterprises Inc (CFO · Feb 20, 2008 – Jul 29, 2010 · Past) | Chief Financial Officer · Sep 14, 2011 – Sep 14, 2011 · Past |
All 15 people
| Person | Seat |
|---|---|
| Robert Benjamin Stein Other companies: PolyPid Ltd. (Director · Since at least Mar 18, 2026) | Director · Mar 25, 2024 – Mar 25, 2024 · Past |
| Andrew Slee | Chief Development Officer · Since at least Nov 5, 2026 |
| Drew Larner | Director · Feb 12, 2007 – Feb 17, 2007 · Past |
| Gregory Ekizian | Director · Feb 12, 2016 – Jun 17, 2016 · Past |
| Khalil Barrage | Director · May 3, 2021 – Mar 25, 2024 · Past |
Log in to ask 6ix AI your own questions about Protagenic Therapeutics, Inc.